Palisade Bio, Inc. PALI
1.01 USD -0.02 (-1.94%)
Regular-session close
1.00 -0.01 -0.99%
Pre-market · Nov 18, 5:03 AM ET
0.99 Day range 1.04
0.99 52-week range 2.86
- YTD
- -57.02%
- 1 year
- -51.21%
News
benzinga.com Palisade Bio Analysts Slash Their Forecasts After Q3 Results Palisade Bio, Inc. (NASDAQ:PALI) reported a wider-than-expected loss for the third quarter on Tuesday.
benzinga.com Palisade Bio Analysts Slash Their Forecasts After Q3 Results Palisade Bio missed Q3 loss estimates at 7¢/share. Shares rose 3.1% as analysts cut price targets; ASCENTRA trials advance.benzinga.com Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16 Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.
benzinga.com HC Wainwright & Co. Maintains Buy on Palisade Bio, Lowers Price Target to $5 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Palisade Bio (NASDAQ:PALI) with a Buy and lowers the price target from $7 to $5.
benzinga.com Palisade Bio Q3 EPS $(0.07) Misses $(0.06) Estimate Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 81.58 percent increase over losses of…
benzinga.com Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027 PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability29 of…
benzinga.com Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The…
